| INTRODUCTION
Mycophenolatemofetil(MMF),animmunosuppressantusedinhuman medicineforsolidorgantransplantation,isbeingincreasinglyapplied totreatmentofimmune-mediateddisease (AbdRahman,Tett,&Staatz, 2013; Kuypersetal.,2010; Staatz&Tett,2007) .Mycophenolatehas beenpopularinhumanmedicineduetorapidityofonsetandreadily availableintravenousandoralformulations (Allison&Eugui,2000) .The useofMMFasanimmunosuppressantinveterinarymedicineisbased onretrospectivestudiesindogsandcats (Abelsonetal.,2009; Bacek &Macintire,2011; Deweyetal.,2010; Yukietal.,2007) .Theactive metabolite,mycophenolicacid(MPA),isareversibleinhibitorofinosinemonophosphatedehydrogenase(IMPDH),acriticalenzymeinthe denovoguanosinenucleotidesynthesispathwayrequiredforproliferationofactivatedlymphocytes (Bullingham,Nicholls,&Kamm,1998; Staatz & Tett, 2007) . Inhibition of IMPDH results in predominantly lymphocyte-specificimmunosuppressioninhibitingcell-mediatedand humoralimmuneresponses (AbdRahmanetal.,2013; Allison&Eugui, 2000; Langmanetal.,1996; Sankatsingetal.,2008) .
Selectivity for a specific immunosuppressive protocol depends uponcliniciandecision-making,patient'sclinicalstatus,andfinancial considerations.Inaccordancewithguidelinesforspecificdiseases,a common protocol is daily administration of prednisone at an immunosuppressivedose.Adverseeffectsofhigh-dosecorticosteroidsinclude gastric ulceration, steroid-hepatopathy, muscle weakness, and iatrogenichyperadrenocorticism.Additionally,monotherapywithglucocorticoidsisfrequentlyinadequatefordiseasecontrol.Alternative immunosuppressive agents may be indicated and can limit the undesirable side effects of corticosteroids. However, these drugs are not without risks including myelosuppression, hepatotoxicity, gastrointestinal disturbances, and other drug-specific systemic effects; therefore,regularmonitoringofcompletebloodcounts(CBC),serum biochemistry, and where possible, effective concentrations are recommended (Viviano,2013) .Inpediatricanimals,immunosuppression ThisworkwasperformedjointlyattheUniversityofMissouriandAuburnUniversity. poses additional challenges in part due toage-relateddifferences in drug metabolism, where existing safety, efficacy and toxicity data maylackaccuracywhendosesareextrapolatedfromstudiesinadult animalstoyoungerimmaturedogs (Adusumalli,Gilchrist,Wichmann, Kucharczyk, & Sofia, 1992; Tassinari, Benson, Elayan, Espandiari, & Davis-Bruno,2011) .
Thereisaneedforaneffectiveimmunosuppressantforjuvenile/ pediatric dogs in clinical and research settings. Noninfections, inflammatory brain diseases including steroid responsive meningitisarteritis occur in juvenile/pediatric dogs, and immunosuppression is required for successful treatment outcome (Tipold & Schatzberg, 2010) .Mycophenolatehasbeenusedsuccessfullyinhumanpediatric renal transplant patients, reflecting a possible therapeutic option in juveniledogsrequiringimmunosuppressionaspartoftheirtreatment regimen (Dong etal., 2014; Downing, Pirmohamed, Beresford, & Smyth,2013) .AdministrationofMMFhasalsoenhancedtheefficacy ofgenetherapyforDuchennemusculardystrophyinadultdogs (Shin etal., 2012) . Based on these findings, MMF has been administered incombinationwithgenetherapyinourTPP1nullDachshundmodel for neuronal ceroid lipofuscinosis (NCL). However, pharmacokinetic anddynamicinformationregardingMMFinjuvenile/pediatricdogsis lacking (Ellinwoodetal.,2011; Shinetal.,2012; Tipold&Schatzberg, 2010) .
AdverseeffectsofMMFindogsincludeacuteseveregastrointestinaltoxicity (Neerman&Boothe,2003) .ThisissimilartogastrointestinalsignsinpeoplereceivingMMF (Arns,2007; Parfitt,Jayakumar,& Driman,2008) .Inhumans,thisisthemostcommoncauseforcessation of treatment, occurs in a non-dose-dependent fashion, and has been reported long after commencing therapy (Hood & Zarembski, 1997; Staatz&Tett,2014; Yuetal.,1998) .Intheauthors'experience, gastrointestinalsideeffectsmaybelife-threateninginpediatricdogs (Neerman & Boothe, 2003) . Pharmacokinetic and pharmacodynamic evaluationisanimportantfirststepinestablishingMMFasaviable immunosuppressantinthisagecohortofdogs.
A pharmacodynamic assay used previously in the dog for MMF evaluatedinhibitionofIMPDHenzymeactivity,withanIMPDHIC 50 of 200μg/mL in adult dogs (Langman etal., 1996) . This assay measuresanenzymerequiredforbiosynthesisofpurinenucleotides,with the assumption that that major mechanism for immunosuppression is inhibition of DNA synthesis of lymphocytes. Our laboratory has developed a highly sensitive, whole blood flow cytometric assay of lymphocyte proliferation which evaluates any mechanism by which MMF prevents lymphocyte proliferation (Bishop KA, 2016; Nafe, 2013) . In healthy dogs, the lymphocyte proliferation IC 50 for MPA was 106.3±157.7nM (0.033±0.05μg/ml) (Bishop KA, 2016) . Of note, this concentration is substantially lower than the previously published reports on the IMPDH IC 50 in adult dogs (Langman etal., 1996) .Itisconsistentwithhumanstudiesandwithinasingledilution oftheIC50forlymphocyteinhibitioninarecentcaninestudy (Guzera, Szulc-Dabrowska,Cywinska,Archer,&Winnicka,2016; deLathouder, Gerards,deGroot,Valkhof,&Aarden,2002) .Inastudyofadultcanine pharmacokinetics,asingledoseofMMFledtobloodconcentrations of10μg/ml,whichiswithintherangeofdetectionofourassay (Lange etal.,2008 
| MATERIALS AND METHODS

| Animals
Eight(intact,sixmale,twofemale)age-matchedjuvenile(120±7days) miniature longhaired Dachshunds (3.69±0.84kg) from a purposebred colony were studied (Awano etal., 2006; Katz etal., 2014) . 
| Mycophenolate mofetil
| Blood sampling
Bloodwascollectedviathejugularcatheterspriortodosing(0min)andat 10, 20and50min, andthen1, 1.5, 2, 3, 4, 6, 9, 12and24hrafterMMF administration. Collected blood at each time point was placed in tubes containing ethylene diamine tetra-acetate (EDTA; 1ml) and/or lithium heparin(0.5ml).SamplesfromEDTAtubeswereusedforpharmacokinetic analysis.Lithiumheparinsampleswereusedforpharmacodynamicsanalysis.Lithiumheparinsampleswerenotcollectedforthe10-min,20-min, and40-mintimepoints.TheEDTAsampleswerecentrifugedwithin1hr, and plasma was banked at −20°C prior to the mycophenolic acid pharmacokineticassay (Staatz&Tett,2007) .Thejugularcatheterswereused andmaintainedaspreviouslydescribed (Carnes,Axlund,&Boothe,2011) .
| Mycophenolic acid assay
Samples were centrifuged for 10min at 1900g within 2hr of collection. Plasma was harvested and frozen at −20°C until analysis. Osos,CA,USA).Theupperandlowerlimitsofquantitationare30.0 and 0.2 μg/ml,respectively. Allcontrols predicted within 6.5+3.2%
(accuracy) whereas the coefficient of variation (precision) using the manufacturer'squalitycontrolsforthetimeperiodoursampleswere analyzedwaslessthan2%forall3controls.
| T lymphocyte proliferation assay
T lymphocyte proliferation was evaluated using an assay previously validatedinourlaboratoryagainstMPA(BishopKA,2016).A1:10di-lutionofwholebloodandcRPMI(RPMI100ml+FBS10ml+100μl dilutedβ-mercaptoethanol)withorwithoutmitogenswasplated(12-wellflat-bottomplate353043;Falcon,Corning,NY,USA)ineachof two wells at a final volume of 1250μl per well. Mitogens added to one well included concanavalin A (ConA) (20μg/ml) and LPS (15μg/ ml) (Nafe, 2013; Nafe, Dodam, & Reinero, 2014 Analysis was performed using a CyAn ADP Flow Cytometer 
| RESULTS
| Adverse effects
Allsixdogsappearedtotolerateoraladministrationofasingledose ofMMFwithnovisibleindicatorsofadverseevents.Alldogs,includingthetwountreatedcontroldogs,hadnormalvitalparametersand physicalexaminationsatthe0-,12-,and24-hrtimepoints.
| Pharmacokinetics
Thepharmacokineticdatainsixtreateddogsincludingmean±SD,CV, Rahmanetal.,2013; Downingetal.,2013; Staatz&Tett,2007 ,2014 .
| DISCUSSION
The concentration of MPA required to cause 50% IMPDH inhibition(I 50 )inhumansis2.0-5.0μg/ml (Langman,LeGatt,&Yatscoff, 1995) .However,thereismarkedvariabilitybetweenspecies.Indogs, theIMPDHIC 50 occursat200μg/mlofMPA (Langmanetal.,1995 (Langmanetal., , 1996 .However,ourlymphocyteproliferationassaydemonstratedan IC 50 at <0.04μg/ml (Bishop KA, 2016) .This concentration is similar toacytokineassayperformedinpeopleandwaswithin1dilutionof arecentlypublishedcaninestudy (Guzeraetal.,2016; deLathouder etal., 2002) . Importantly, these concentrations were achieved using differentpharmacodynamicassays,suggestingthatMPAmayinhibit lymphocyte proliferation by an IMPDH-independent mechanism.
Both assays focus on in vitro effects without modification or alteration metabolite distribution of the immunosuppressant; thus, some differencescouldbeexpectediftheassayswereusedexvivo.Thisis Live, Proliferating CD5+ T cells etal.,1998) .Whilethesejuveniledogsdisplayedrapidabsorption,the secondpeakconcentrationwasnotapparentinalldogs. Thisisincontrasttoadultdogs,whererapidoralabsorptionandmarkedenterohepaticrecirculationwereobserved(Langmanetal.,1996) .Reported oral bioavailability in the canine species ranges from 54 to 87% (Langmanetal.,1996; Lupu,McCune,Kuhr,Gooley,&Storb,1996) .
Inpeople,MMFexhibitsnonlinearpharmacokineticswithdecreasing bioavailabilityathigherdoses.Thisisincontrasttotheadultdogin whichAUC was not significantly altered with increasing doses from 10to30mg/kg (Langeetal.,2007; deWinter,Mathot,Sombogaard, Vulto, &van Gelder, 2011 ). In the current study, 13mg/kg MMF as single administered dosewas selected based on lower doses avoidingdose-relatedsideeffectswithoutimpactingoveralldrugexposure (Langeetal.,2007; Langmanetal.,1996) .Thisisthedoseusedinour genetherapymodelforNCLandisconsideredthemaximumtolerated dose for long-term administration based on the development of severegastrointestinalsideeffects.
Overall, the pharmacokinetics in these juvenile dogs are suggestiveofrapidabsorptionandconversionofMMFtoMPAaspreviously reported in adult dogs; however, the T1/2, terminal rate constant, C max ,andAUC 0-∞ showedmarkeddifferences,comparedtopreviously publishedreportsinhumanpediatrictransplantpatientsandhealthy adults. As results obtained by immunoassay tend to be increased compared to HPLC, these decreases are unlikely to be due to the assay (Weberetal.,2002) .Thedatareportedinthisstudyweremore comparable to studies in adult dogs, although in the T1/2 was prolongedcomparedtopreviouspublishedreportsinadultdogs(Table2) (Downingetal.,2013; Langeetal.,2007; Staatz&Tett,2007) .
The decreased AUC and C max observed in dogs compared to humans may reflect differences in the intestinal microbiome, drug metabolism, and clearance resulting in decreased AUC and C max for individuals, species, and age groups (Table2) (Deng & Swanson, 2015; Whitley & Day, 2011) . Enterohepatic recirculation accounts for10%-40%oftheAUCinpreviousstudies (Downingetal.,2013; Staatz &Tett, 2007) . Reduced contribution from impaired enterohepatic circulation has been shown to significantly decrease the AUC followingoralMMF (vanGelder,Klupp,Barten,Christians,&Morris, 2001 (Weber etal., 2002) . The pharmacokinetic parameters in these juvenile dogs show significant interindividualvariability even under tightly controlled, experimental conditions.This is consistentwith previous reports in people,which showedpronouncedinterindividualvariationwith32%-60%variance
for AUC 0-12 (Kuypers etal., 2010) . Daily variability in enterohepatic recirculation, individual microbiota, or age-dependent differences in P-glycoproteinsmayaccountforthedifferencesobservedhere (Deng & Swanson, 2015; Fanta etal., 2008; Kearns etal., 2003; Tsai etal., 2002) .
PreviousinvitroandinvivostudieshavedemonstratedthatMPA has high potency to inhibit T-cell proliferation in a dose-dependent fashion (Gummert, Barten, Sherwood, van Gelder, & Morris, 1999; Langmanetal.,1996; Sankatsingetal.,2008; Yuetal.,1998) .Inrodents and people, MPA suppressesT-cell proliferation (Abd Rahman etal.,2013; Gummertetal.,1999; Staatz&Tett,2007) .Inhibitionof lymphocyte proliferation was observed at low plasma MPA concentrations after a single dose in humans prior to renal transplantation (Kamar etal., 2009) . In adult dogs, in vitro incubation of MPA with caninelymphocytesandwholebloodresultedindose-dependentinhibitionofIMPDHwith an [I 50 ]of200μg/ml,although thisconcentrationwas not achieved invivo (Lange etal., 2007; Langman etal., 1996; Lupuetal.,1996 (Kilp,Ramirez,Allan,Roepke,&Nuernberger, 2014; Norkus,Rankin,&KuKanich,2015) .Additionally,thepossibility thatplasmaconcentrationsdonottrulyreflecttissueconcentrations shouldalsobeconsidered. 
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